BofA Securities Adjusts Price Target on AptarGroup to $145 From $147, Maintains Neutral Rating
BofA Securities has lowered its price target for AptarGroup (NYSE:ATR) from $147 to $145, while retaining a Neutral rating on the stock. This adjustment comes despite recent positive news for AptarGroup, including an upgrade from Wells Fargo and developments in its nasal delivery systems for clinical studies. AptarGroup specializes in designing and manufacturing dispensing and protection technologies for various markets, including pharmaceuticals and consumer products.
JB Capital LLC Acquires New Position in AptarGroup, Inc. $ATR
JB Capital LLC has acquired a new stake in AptarGroup, Inc. (NYSE:ATR), purchasing 9,703 shares valued at approximately $1.18 million during the fourth quarter. This move comes as AptarGroup's board authorized a $600 million share buyback, indicating a belief that the stock is undervalued, and the company reported strong Q4 results that beat revenue and EPS expectations. Insider activity also occurred, with Gael Touya selling 3,500 shares, reducing their stake by over 11%.
SG Americas Securities LLC Increases Stock Holdings in AptarGroup, Inc. $ATR
SG Americas Securities LLC significantly increased its stake in AptarGroup, Inc. by 262.8% in Q4, acquiring 17,274 additional shares to hold a total of 23,848 shares valued at approximately $2.91 million. AptarGroup recently reported strong Q4 earnings, beating analyst estimates with an EPS of $1.25 and revenue of $962.7 million, and announced a $600 million share buyback program and a quarterly dividend of $0.48 per share. Despite a consensus "Hold" rating from analysts, institutional investors collectively own 88.52% of the company's stock, indicating significant institutional confidence.
How Investors May Respond To AptarGroup (ATR) Powering ENA’s Phase II Intranasal Antiviral Study
AptarGroup's Unidose Powder Nasal Spray System is being used in ENA Respiratory's Phase II clinical study for an intranasal antiviral, reinforcing Aptar's shift towards pharmaceutical drug delivery. This partnership, alongside another recent collaboration with LTR Pharma, highlights the growing integration of Aptar's nasal delivery technology in clinical programs. While these developments are positive for Aptar's investment narrative, ongoing legal expenses and uneven demand in other sectors remain factors investors should consider.
Assenagon Asset Management S.A. Has $1.25 Million Stock Position in AptarGroup, Inc. $ATR
Assenagon Asset Management S.A. significantly increased its stake in AptarGroup, Inc. (NYSE:ATR) by 390% in the fourth quarter, bringing its total holdings to 10,276 shares valued at approximately $1.25 million. AptarGroup also reported strong quarterly earnings, beating expectations with $1.25 EPS and $962.7 million in revenue, leading to a new $600 million share buyback authorization and a $0.48 quarterly dividend. Despite a "Hold" consensus rating from analysts, institutional investors collectively own about 88.5% of the company's stock.
AptarGroup, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
AptarGroup, Inc. is experiencing a stock evaluation revision due to mixed technical indicators and a competitive packaging industry. While the stock showed a slight weekly gain, its longer-term performance has significantly lagged the S&P 500, with bearish signals from MACD and Bollinger Bands. The company's year-to-date performance is a modest gain, but its one, three, five, and ten-year returns show underperformance compared to the broader market.
AptarGroup Inc Stock: Packaging Leader Positions for Sustainable Pharma and Beauty Growth Amid Sector Tailwinds
AptarGroup Inc is positioned as a leader in specialized dispensing and packaging solutions, benefiting from increasing demand in the pharmaceutical and beauty industries. The company's focus on sustainability, innovation, and a diversified business model with strong market presence in Pharma, Beauty + Home, and Food + Beverage segments provides a competitive edge. This makes AptarGroup a compelling option for investors seeking exposure to resilient consumer and healthcare trends, despite potential risks from raw material costs and macroeconomic fluctuations.
AptarGroup Inc Stock: Packaging Leader Positions for Sustainable Pharma and Beauty Growth Amid Sector Tailwinds
AptarGroup Inc (ISIN: US0383361039) is positioned as a leader in specialized dispensing and packaging solutions, benefiting from strong demand in the pharmaceutical and beauty sectors. The company's focus on innovation, sustainability, and diversified segments like Pharma, Beauty + Home, and Food + Beverage, provides a competitive edge. North American investors are encouraged to monitor its sustainability initiatives, innovation pipeline, and consistent performance in a resilient market.
ATR Technical Analysis & Stock Price Forecast
The article provides a technical analysis for Aptargroup Inc (ATR), indicating a "Strong Sell" consensus based on various indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and analyses Aptargroup's performance relative to its moving averages. Key findings include ATR trading below its 60-day and 200-day moving averages, with a MACD signaling a strong sell.
Tudor Investment Corp ET AL Sells 33,999 Shares of AptarGroup, Inc. $ATR
Tudor Investment Corp ET AL significantly reduced its stake in AptarGroup, Inc. (NYSE:ATR) by selling 33,999 shares, now owning 29,116 shares valued at $3.892 million. Despite this, AptarGroup reported strong quarterly earnings, beating EPS estimates and increasing revenue, while its board approved a $600 million share buyback program. Analyst sentiment for AptarGroup is mixed, with a consensus "Hold" rating but some recent upgrades, and the stock maintains a high institutional ownership of about 88.5%.
Global Pump and Dispenser Market to Reach USD 84.6 Billion by 2036 Led by North America and AptarGroup Inc. Innovation
The global pump and dispenser market is projected to reach USD 84.6 billion by 2036, growing at a CAGR of 7.5% from its 2026 valuation of USD 41.1 billion. This growth is driven by increasing demand across personal care, pharmaceuticals, food packaging, and household products, with a focus on innovation, hygiene, and sustainability. North America is a key driver, alongside companies like AptarGroup Inc.
Nordea Investment Management AB Invests $7.31 Million in AptarGroup, Inc. $ATR
Nordea Investment Management AB has acquired a new stake in AptarGroup, Inc. (NYSE:ATR) worth approximately $7.31 million, representing about 0.09% of the company. This comes as AptarGroup reported strong Q4 earnings, surpassing EPS estimates and seeing a 13.5% increase in revenue year-over-year. The company also announced a $600 million share repurchase program and a quarterly dividend, while analysts have provided varied ratings with an average target price of $173.00.
Dropper Market Set to Boom Rapidly by 2033 | AptarGroup Inc. • Berry Global Inc. • Silgan Holdings Inc
A new report by Coherent Market Insights forecasts rapid growth for the Dropper Market by 2033, driven by current trends, growth drivers, and technological advancements. The report offers an in-depth analysis of the industry, including competitor analysis, regional market evaluation, and key insights for businesses. Major companies covered include AptarGroup Inc., Berry Global Inc., and Silgan Holdings Inc., with segmentation across pharmaceuticals, cosmetics, food and beverage, and other sectors.
Vanguard reports 0 shares of AptarGroup (NYSE: ATR) after internal realignment
Vanguard has filed an amended Schedule 13G/A, reporting 0 shares beneficially owned in AptarGroup (NYSE: ATR), representing 0% of the common stock. This change is due to an internal realignment within Vanguard on January 12, 2026, where certain subsidiaries now report their holdings separately. Consequently, Vanguard no longer claims beneficial ownership over these securities.
AptarGroup Inc stock faces CEO transition in 2026 amid analyst upgrades and pharma delivery wins
AptarGroup Inc. is undergoing a CEO transition in September 2026, with Gael Touya appointed to succeed the current leader. The company is receiving analyst upgrades due to its strong balance sheet, defensive pharmaceutical exposure, and new collaborations in nasal drug delivery systems. Despite a recent stock decline, these strategic moves and financial health position AptarGroup as a resilient option for US investors navigating market volatility.
Aptar to gain new CEO later this year
Aptar is set to appoint a new CEO later this year. The article, by Jim Johnson, also touches on other plastics industry news such as rising polystyrene and PVC prices, and legal and regulatory updates concerning pollution and reuse targets.
AptarGroup’s Nasal Devices Gain Ground In Respiratory Trials And Leadership Shift
AptarGroup's nasal devices are gaining traction in respiratory trials, highlighted by the use of their Unidose Powder Nasal Spray System in ENA Respiratory's Phase II trial for INNA-051, a non-vaccine approach to preventing viral respiratory infections. This development positions AptarGroup as a key player in advanced nasal drug delivery technologies, aligning with the strategic vision of incoming President Gael Touya. Investors are advised to monitor the expanded use of Aptar's platforms in clinical trials and the strategic execution of its leadership transition.
AptarGroup (ATR) CFO Vanessa Kanu receives 10,960-share stock grant
AptarGroup (ATR) CFO Vanessa Kanu received a grant of 10,960 shares of common stock as compensation, as detailed in a recent SEC Form 4 filing. This award, recorded at no purchase price, increases her direct stake in the company to 24,646 shares, further aligning her interests with shareholders. The transaction, dated March 19, 2026, was a stock grant and not a market purchase, with no derivative securities involved.
ATR SEC Filings - Aptargroup 10-K, 10-Q, 8-K Forms
This page provides access to Aptargroup (ATR) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider trading forms. It highlights recent filings such as a Form 144 for proposed share sales, insider transactions by executives, Morgan Stanley's beneficial stake, and details regarding a $600M senior notes offering. The company is a global supplier of dosing and dispensing technologies with segments in Pharma, Beauty, and Closures.
AptarGroup (ATR) Segment President Hedi Tlili receives 10,803-share stock grant
AptarGroup (ATR) Segment President Hedi Tlili was granted 10,803 shares of common stock as a stock award with a reported price of $0.00 per share. This compensation-related acquisition increased Tlili's direct holdings to 21,323 shares of AptarGroup common stock. The transaction was detailed in a Form 4 SEC filing, indicating it was a stock grant rather than a market purchase.
AptarGroup Hires New CEO
AptarGroup, Inc. has appointed Gael Touya as its new CEO, succeeding Stephan Tanda, who will retire by year-end. Touya, with over 30 years at Aptar, previously served as President of Aptar Pharma, and his internal promotion is viewed by analysts as a move towards strategic continuity. The company's stock shows short-term weakness but longer-term strength, with analysts maintaining a "Market Perform" rating.
APTARGROUP (NYSE: ATR) awards stock options and shares to accounting chief
APTARGROUP (NYSE: ATR) Chief Accounting Officer Daniel Ackerman received equity compensation awards, including stock options for 2,967 shares at an exercise price of $123.97 and a grant of 762 common shares. These awards increase his direct common stock holdings to 30,369 shares. The stock options will vest in three equal installments starting on the first anniversary of the grant date and expire in 2036.
AptarGroup (ATR) segment president receives option and stock grants
AptarGroup (ATR) Segment President Marc Prieur reported receiving equity compensation awards, including 10,153 stock options and 2,609 shares of Common Stock. These grants increase his direct holdings to 16,354 shares and are considered compensation rather than open-market transactions. The stock options vest in three equal installments starting one year from the grant date.
AptarGroup (ATR) EVP granted 3,021 options plus 776 shares
AptarGroup's EVP and Chief Legal Officer, Irene Elizabeth Hudson, received equity-based compensation as reported in a recent SEC Form 4 filing. She was granted stock options for 3,021 shares with an exercise price of $123.97, set to vest in three equal installments starting one year from the grant date and expiring on March 19, 2036. Additionally, she received a direct grant of 776 common shares, increasing her directly held common stock to 1,465 shares.
AptarGroup (NYSE: ATR) awards options and stock to executive
AptarGroup (NYSE: ATR) Segment President Gael Touya received equity compensation awards, detailed in a Form 4 SEC filing. He was granted stock options for 8,830 shares with an exercise price of $123.97, vesting in three annual installments, and 2,269 shares of common stock, increasing his direct holdings to 29,563 shares. These awards are part of his compensation rather than open-market transactions.
AptarGroup (NYSE: ATR) CEO receives new stock and option awards
AptarGroup's President and CEO, Stephan B. Tanda, received new equity awards as part of his compensation, including a stock option for 53,691 shares and a grant of 13,796 common shares. These awards are compensation-related and not open-market purchases, increasing his direct common stock holdings to 214,782 shares. The stock option vests in three equal installments starting one year from the grant date and expires on March 19, 2036.
AptarGroup (ATR) CFO granted 16,858 options and 4,332 shares
AptarGroup's EVP & CFO, Vanessa Kanu, has been granted 16,858 stock options with an exercise price of $123.97, vesting over three years, and 4,332 shares of Common Stock. These equity awards are part of her compensation, increasing her direct holdings to 13,686 shares and showing her stock options to 16,858. This Form 4 filing indicates compensation-related equity awards rather than open-market purchases or sales.
AptarGroup (ATR) Asia president awarded 7,515 options and 1,931 shares
AptarGroup, Inc.'s President, Asia, Xiangwei Gong, received equity awards on March 19, 2026. These awards include stock options for 7,515 shares with an exercise price of $123.97, vesting in three equal installments, and a grant of 1,931 common shares. Following these transactions, Gong directly holds 11,031 common shares and indirectly holds 642 shares through a 401(k) trust.
AptarGroup (ATR) grants stock options and shares to segment president
AptarGroup (ATR) segment president Hedi Tlili received compensation-related equity grants. He was granted 8,394 stock options with an exercise price of $123.97 per share, vesting over three years, and 2,157 shares of common stock, bringing his direct common stock holdings to 10,520 shares. This transaction was disclosed in a Form 4 SEC filing.
AptarGroup (NYSE: ATR) CHRO granted stock options and shares
AptarGroup's Chief Human Resources Officer, Shiela Vinczeller, received routine equity compensation on March 19, 2026. This included a stock option grant for 6,592 shares with an exercise price of $123.97, vesting in three annual installments, and a direct grant of 1,694 shares of common stock. Following these transactions, her direct holdings in AptarGroup common stock totaled 26,751 shares.
Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray
AptarGroup, Inc. announced that its Unidose (UDS) Powder Nasal Spray System is being used in ENA Respiratory's Phase II clinical study of INNA-051. INNA-051 is an investigational nasal spray aimed at protecting against symptomatic viral respiratory infections. This collaboration highlights the growing importance of intranasal delivery technologies in developing new, non-vaccine approaches to respiratory disease prevention.
[Form 4] APTARGROUP, INC. Insider Trading Activity
AptarGroup, Inc.'s Chief Human Resources Officer, Shiela Vinczeller, reported a routine disposition of 139 common shares on March 17, 2026. These shares, valued at $129.50 each, were withheld to cover tax liabilities associated with equity compensation. Following this transaction, Vinczeller directly holds 25,057 shares of AptarGroup common stock.
[Form 4] APTARGROUP, INC. Insider Trading Activity
AptarGroup, Inc. Segment President Gael Touya reported a tax-related disposition of 320 common shares at $129.97 per share to cover tax obligations on March 17, 2026. Following this transaction, Touya directly owns 27,294 shares. This information was disclosed in a neutral SEC Form 4 filing.
AptarGroup (NYSE: ATR) exec has shares withheld for taxes
AptarGroup's President, Asia, Xiangwei Gong, had 213 common shares withheld for tax obligations on March 17, 2026, at a price of $129.50 per share. This non-market transaction was a routine tax-withholding disposition. Following this event, Gong directly holds 9,100 common shares and indirectly holds an additional 642 shares through a 401(k) trust.
AptarGroup (NYSE: ATR) CLO uses 37 shares for tax withholding
AptarGroup's EVP and Chief Legal Officer, Irene Elizabeth Hudson, used 37 shares of common stock at $129.50 per share on March 17, 2026, for tax withholding purposes. This transaction, revealed in an SEC Form 4 filing, is a routine adjustment rather than a market sale. After this, she directly holds 689 common shares, retaining a substantial equity stake in the company.
AptarGroup (NYSE: ATR) executive uses 273 shares to cover taxes
AptarGroup's Segment President, Hedi Tlili, reported a tax-withholding disposition of 273 shares of common stock at $129.97 per share to satisfy tax obligations. This non-market transaction is classified as "F" on the Form 4, indicating it was for tax liabilities rather than an open-market sale. After this transaction, Hedi Tlili directly holds 8,363 AptarGroup shares.
Aptar appoints Gael Touya as CEO
AptarGroup, a global leader in dispensing, active packaging, and material science solutions, has announced the promotion of Gael Touya to the role of Chief Executive Officer. Touya, who has been with Aptar for 23 years, previously served as President of Aptar Beauty and then President of Aptar Pharma. He will succeed Stephan B. Tanda, who is stepping down from his role.
AptarGroup Hires New CEO
AptarGroup has appointed Gael Touya as its new CEO, succeeding Stephan Tanda. Touya brings over 30 years of experience with Aptar, previously serving as President of Aptar Pharma. William Blair maintains a Market Perform rating on the stock, viewing the internal promotion as a sign of strategic continuity.
AptarGroup Inc Stock (ISIN: US0383361039) Faces Headwinds Amid CEO Succession and Analyst Downgrade
AptarGroup Inc (ISIN: US0383361039) is undergoing a CEO transition with Stephan Tanda retiring in September 2026 and Gael Touya, President of Aptar Pharma, slated to succeed him. Despite solid Q4 2025 results and a renewed share buyback program, the stock faces scrutiny from a recent Zacks Strong Sell rating due to downward revisions in earnings estimates. The company's resilience is supported by its pharma packaging segment and a 2.2% prospective dividend yield, although it must navigate key risks like leadership transition execution and competitive pressures.
Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year
AptarGroup, Inc. has announced the appointment of Gael Touya as its new President and Chief Executive Officer, effective September 1, 2026. Touya, who has been with the company for over 30 years and most recently served as Aptar Pharma President, will succeed Stephan B. Tanda. Tanda, who has led Aptar since 2017, will transition to an advisory role until the end of the year before retiring from the Board.
Aptar Announces Gael Touya as its Next Chief Executive Officer Stephan B. Tanda to Retire by the End of the Year
AptarGroup, Inc. has announced Gael Touya as its new President and Chief Executive Officer, effective September 1, 2026. Touya, previously Aptar Pharma President, will succeed Stephan B. Tanda, who is retiring after serving as CEO since 2017. Tanda will remain an advisor through the end of the year to ensure a smooth transition.
AptarGroup CEO Stephan Tanda to retire, Gael Touya named successor
AptarGroup, Inc. announced that CEO Stephan Tanda will retire on September 1, 2026, and Gael Touya, President of Aptar Pharma, will succeed him. Touya's employment agreement includes an initial annual base salary of $1,060,000 and significant incentive awards, along with provisions for severance. Tanda will remain as a strategic advisor, and the company also granted one-time restricted stock awards to two other executives.
Aptar Announces Gael Touya as its Next Chief Executive Officer Stephan B. Tanda to Retire by the End of the Year
AptarGroup, Inc. (NYSE:ATR) has announced that Gael Touya will succeed Stephan B. Tanda as President and Chief Executive Officer, effective September 1, 2026. Touya, with over 30 years at Aptar and most recently President of Aptar Pharma, was unanimously chosen by the Board after a thorough succession process. Tanda will retire by the end of 2026 after leading significant growth and expansion for the company since 2017.
AptarGroup (NYSE: ATR) taps Gael Touya as CEO, sets new pay deals
AptarGroup (NYSE: ATR) has announced that Gael Touya will take over as CEO from Stephan Tanda, effective September 1, 2026. Touya's compensation package includes a base salary of $1,060,000, substantial bonus and long-term incentive targets, and deferred compensation. The transition plans also involve Tanda remaining as a strategic advisor and board member, and retention equity awards for other key executives to ensure leadership continuity.
[Form 4] APTARGROUP, INC. Insider Trading Activity
APTARGROUP, INC. Segment President Gael Touya reported a routine, tax-related disposition of 791 shares of common stock at $129.48 per share to cover tax obligations from equity compensation. This transaction, coded as F, is a non-market withholding and not considered a discretionary sale, thus having limited informational value regarding Touya's view of AptarGroup's prospects. Following this, Touya directly holds 27,614 shares of AptarGroup common stock.
London Co. of Virginia Has $130.03 Million Stock Holdings in AptarGroup, Inc. $ATR
London Co. of Virginia reduced its stake in AptarGroup, Inc. (NYSE:ATR) by 4.7% but still holds 972,857 shares valued at approximately $130.03 million. AptarGroup recently reported strong earnings, beating analyst expectations, and announced a $600 million share buyback program and a quarterly dividend of $0.48, highlighting a focus on shareholder returns. Institutional investors collectively own a significant 88.52% of the company's stock, and analysts maintain a "Hold" rating with an average target price of $170.25.
Speece Thorson Capital Group Inc. Purchases 16,815 Shares of AptarGroup, Inc. $ATR
Speece Thorson Capital Group Inc. significantly increased its stake in AptarGroup, Inc. (NYSE:ATR) by 20.3%, purchasing an additional 16,815 shares to hold a total of 99,470 shares valued at approximately $13.3 million. This makes AptarGroup the firm's 20th largest holding, accounting for about 2.7% of its portfolio. The article also highlights AptarGroup's strong Q4 earnings, an authorized $600 million share buyback, a $0.48 quarterly dividend, and a consensus "Hold" rating from analysts with an average price target of $170.25.
Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray
AptarGroup announced that its proprietary intranasal delivery system is being used in LTR Pharma Limited’s Phase II clinical study for SPONTAN®, an investigational nasal spray for erectile dysfunction. This collaboration highlights Aptar Pharma's commitment to advancing complex intranasal therapies through robust delivery platforms and expertise, with Nanopharm optimizing the formulation and Noble providing human factors support. The partnership aims to ensure reliable and consistent intranasal drug delivery as SPONTAN® progresses through clinical development.
ATR - Aptargroup Latest Stock News & Market Updates
This page provides the latest news and market updates for Aptargroup (NYSE: ATR), offering insights for investors and traders. AptarGroup specializes in drug delivery, digital health, and consumer dispensing technologies, with news often highlighting new delivery systems, clinical collaborations, acquisitions, and financial updates. The company announced its Q3 2020 results with an 8% sales increase and declared a quarterly dividend of $0.36 per share.
Crawford Investment Counsel Inc. Grows Position in AptarGroup, Inc. $ATR
Crawford Investment Counsel Inc. significantly increased its stake in AptarGroup, Inc. by 41.4% in the third quarter, now owning 244,491 shares valued at over $32 million. This move comes as AptarGroup reported strong Q4 earnings, beating estimates with $1.25 EPS and $962.7 million in revenue, and announced a new $600 million share repurchase program and a $0.48 quarterly dividend. Institutional investors collectively hold approximately 88.52% of the company's stock.
